iShares Core S&P 500 ETF vs Nuvation Bio Inc. Class A Common Stock — how do they compare? iShares Core S&P 500 ETF trades at $779.84 (market cap $899.63B), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: iShares Core S&P 500 ETF is far larger — about 526.1× Nuvation Bio Inc. Class A Common Stock's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| IVV | NUVB | |
|---|---|---|
Market Cap | $899.63B | $1.71B |
Volume | 3,643,926 | 5,448,712 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $9.54 |
52-Week Low | $634.93 | $3.41 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $1.30B |
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $780.60, down 0.25% on the day. Technical indicators show a bullish trend with moving averages strongly positive, though RSI suggests potential overbought conditions near-term. The ETF remains a core holding for broad US equity exposure, with recent news highlighting strong corporate earnings growth expectations of 35% for 2026. Market sentiment is mixed as valuations attract scrutiny despite index strength.
Outlook remains constructive given the S&P 500's earnings momentum and historical seasonal trends favoring year-end rallies. Key risks include potential profit growth deceleration to 15% in 2027 and concentration in top holdings. The ETF offers diversified exposure to large-cap US equities, with the current level near pivot point support providing a strategic entry zone for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →